FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136303113> ?p ?o ?g. }

• W3136303113 endingPage "1484" @default.
• W3136303113 startingPage "1484" @default.
• W3136303113 abstract "Immune checkpoints inhibitors (ICIs) were considered as second-line treatments in metastatic urothelial carcinoma (mUC) based on better survival benefit and safety profile than chemotherapy (CTX). We aimed to assess different ICIs regimens in the efficacy and safety for front-line treatments in mUC patients. A comprehensive literature search was performed and Phase II-III randomized controlled trials (RCTs) on ICIs for patients with mUC were included. The outcome was evaluated by overall survival (OS), progression of free survival (PFS), objective response rate (ORR), and grade 3–5 adverse events. Network meta-analysis was used to estimate the effect size. Surface under cumulative ranking curves (SUCRAs) were applied to rank the included treatments for each outcome. Results: The survival benefit of a single ICI was non-inferiority to chemotherapy (CTX). Although no superior effects were indicated, combination therapy (either ICIs plus CTX or ICIs plus ICIs) presented better OS compared with CTX alone. In terms of PFS, combination therapy produced a noticeable benefit over CTX. Regarding the SUCRA ranking, atezolizumab plus CTX was associated with the best ranking for OS and pembrolizumab plus CTX was the best in PFS. In terms of safety, a single ICI had better safety profile than CTX and combination therapy had a similar risk of grade 3–5 adverse events with CTX. Conclusions: Our NMA results revealed that combination therapy has better ranking compared with monotherapy in OS and acceptable AEs. ICIs alone present non-inferior OS but a lower incidence of AEs compared with CTX." @default.
• W3136303113 created "2021-03-29" @default.
• W3136303113 creator A5008328625 @default.
• W3136303113 creator A5019875995 @default.
• W3136303113 creator A5042622898 @default.
• W3136303113 creator A5042920611 @default.
• W3136303113 creator A5051759845 @default.
• W3136303113 creator A5056534493 @default.
• W3136303113 creator A5069174563 @default.
• W3136303113 creator A5070692207 @default.
• W3136303113 date "2021-03-23" @default.
• W3136303113 modified "2023-10-18" @default.
• W3136303113 title "Immune Checkpoints Inhibitors and Chemotherapy as First-Line Treatment for Metastatic Urothelial Carcinoma: A Network Meta-Analysis of Randomized Phase III Clinical Trials" @default.
• W3136303113 cites W1752338025 @default.
• W3136303113 cites W1893740135 @default.
• W3136303113 cites W1941332786 @default.
• W3136303113 cites W1982967337 @default.
• W3136303113 cites W2015407742 @default.
• W3136303113 cites W2049865778 @default.
• W3136303113 cites W2103257412 @default.
• W3136303113 cites W2103707167 @default.
• W3136303113 cites W2465838633 @default.
• W3136303113 cites W2559804019 @default.
• W3136303113 cites W2588916311 @default.
• W3136303113 cites W2593537476 @default.
• W3136303113 cites W2725931071 @default.
• W3136303113 cites W2760661635 @default.
• W3136303113 cites W2777192533 @default.
• W3136303113 cites W2792643377 @default.
• W3136303113 cites W2890875511 @default.
• W3136303113 cites W2906932524 @default.
• W3136303113 cites W2961042511 @default.
• W3136303113 cites W3010579821 @default.
• W3136303113 cites W3020918038 @default.
• W3136303113 cites W3024551702 @default.
• W3136303113 cites W3036737074 @default.
• W3136303113 cites W3087466624 @default.
• W3136303113 cites W3087883993 @default.
• W3136303113 cites W3092257706 @default.
• W3136303113 doi "https://doi.org/10.3390/cancers13061484" @default.
• W3136303113 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8005008" @default.
• W3136303113 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33807108" @default.
• W3136303113 hasPublicationYear "2021" @default.
• W3136303113 type Work @default.
• W3136303113 sameAs 3136303113 @default.
• W3136303113 citedByCount "4" @default.
• W3136303113 countsByYear W31363031132021 @default.
• W3136303113 countsByYear W31363031132022 @default.
• W3136303113 countsByYear W31363031132023 @default.
• W3136303113 crossrefType "journal-article" @default.
• W3136303113 hasAuthorship W3136303113A5008328625 @default.
• W3136303113 hasAuthorship W3136303113A5019875995 @default.
• W3136303113 hasAuthorship W3136303113A5042622898 @default.
• W3136303113 hasAuthorship W3136303113A5042920611 @default.
• W3136303113 hasAuthorship W3136303113A5051759845 @default.
• W3136303113 hasAuthorship W3136303113A5056534493 @default.
• W3136303113 hasAuthorship W3136303113A5069174563 @default.
• W3136303113 hasAuthorship W3136303113A5070692207 @default.
• W3136303113 hasBestOaLocation W31363031131 @default.
• W3136303113 hasConcept C121608353 @default.
• W3136303113 hasConcept C126322002 @default.
• W3136303113 hasConcept C143998085 @default.
• W3136303113 hasConcept C168563851 @default.
• W3136303113 hasConcept C197934379 @default.
• W3136303113 hasConcept C2775949291 @default.
• W3136303113 hasConcept C2776694085 @default.
• W3136303113 hasConcept C2777701055 @default.
• W3136303113 hasConcept C2780057760 @default.
• W3136303113 hasConcept C2780352672 @default.
• W3136303113 hasConcept C2911057145 @default.
• W3136303113 hasConcept C3019882237 @default.
• W3136303113 hasConcept C71924100 @default.
• W3136303113 hasConcept C95190672 @default.
• W3136303113 hasConceptScore W3136303113C121608353 @default.
• W3136303113 hasConceptScore W3136303113C126322002 @default.
• W3136303113 hasConceptScore W3136303113C143998085 @default.
• W3136303113 hasConceptScore W3136303113C168563851 @default.
• W3136303113 hasConceptScore W3136303113C197934379 @default.
• W3136303113 hasConceptScore W3136303113C2775949291 @default.
• W3136303113 hasConceptScore W3136303113C2776694085 @default.
• W3136303113 hasConceptScore W3136303113C2777701055 @default.
• W3136303113 hasConceptScore W3136303113C2780057760 @default.
• W3136303113 hasConceptScore W3136303113C2780352672 @default.
• W3136303113 hasConceptScore W3136303113C2911057145 @default.
• W3136303113 hasConceptScore W3136303113C3019882237 @default.
• W3136303113 hasConceptScore W3136303113C71924100 @default.
• W3136303113 hasConceptScore W3136303113C95190672 @default.
• W3136303113 hasIssue "6" @default.
• W3136303113 hasLocation W31363031131 @default.
• W3136303113 hasLocation W31363031132 @default.
• W3136303113 hasOpenAccess W3136303113 @default.
• W3136303113 hasPrimaryLocation W31363031131 @default.
• W3136303113 hasRelatedWork W2745896026 @default.
• W3136303113 hasRelatedWork W2904110710 @default.
• W3136303113 hasRelatedWork W2948845624 @default.
• W3136303113 hasRelatedWork W2961042511 @default.
• W3136303113 hasRelatedWork W3028814175 @default.
• W3136303113 hasRelatedWork W3033877262 @default.

• next